In the WHO classification, neuroendocrine tumors have been defined as those in which one or more neuroendocrine markers, such as neuro specific enolase, chromogranin A, and/or synaptophysin, are expressed in at least 50% of cancer cells.

In addition to the surveillance previously recommended for the potential association of GLP-1--based therapy and pancreatic cancer risk, the current data imply that surveillance for a possible increased risk of pancreatic neuroendocrine tumors is warranted.

Many imaging specialists would be more likely to bring attention to subtle areas of increased tracer uptake when there is clinical and/or laboratory evidence of a neuroendocrine tumor, as in this case.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.